Danny Rischin

4 days ago | ajmc.com | Pearl Steinzor |Dirk Arnold |Vincent J. Picozzi |Danny Rischin

Oncology professionals reflect on the unique value of attending the American Society of Clinical Oncology (ASCO) annual meeting—from discovering new clinical trial results to reconnecting with peers from around the world. With major practice-changing research and global thought leadership in one place, ASCO continues to be a can't-miss event for the cancer care community.

6 days ago | ajmc.com | Pearl Steinzor |Danny Rischin

Cemiplimab significantly improved disease-free survival, reducing the risk of recurrence by 68% and distant metastases by 65% in patients with locally advanced cutaneous squamous cell carcinoma (CSCC), explains Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre in Melbourne, Australia. The study (NCT03969004) was presented at the American Society of Clinical Oncology (ASCO) meeting. This transcript was lightly edited; captions were auto-generated.

Jun 5, 2024 | digitalcommons.library.tmc.edu | Danny Rischin |Nicole Basset-Seguin |Dirk Schadendorf |Samantha Bowyer

BACKGROUND: Cemiplimab (LibtayoMETHODS: In this open-label, phase II trial (ClinicalTrials.gov identifier NCT02760498), the cohort of patients ≥18 years old with advanced CSCC received cemiplimab 600 mg intravenously Q4W for up to 48 weeks. Tumor measurements were recorded every 8 weeks. The primary endpoint was objective response rate by independent central review. RESULTS: Sixty-three patients with advanced CSCC were treated with cemiplimab.

Mar 1, 2024 | jitc.bmj.com | Danny Rischin |Nicole Basset-Seguin |Dirk Schadendorf |Samantha Bowyer

Clinical/translational cancer immunotherapy High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.